In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: California Books, Miami, FL, USA
Zustand: New. Artikel-Nr. I-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: Rarewaves.com USA, London, LONDO, Vereinigtes Königreich
Hardback. Zustand: New. Artikel-Nr. LU-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: Rarewaves.com UK, London, Vereinigtes Königreich
Hardback. Zustand: New. Artikel-Nr. LU-9783725867707
Anzahl: Mehr als 20 verfügbar
Anbieter: Home-set, Mannheim, Deutschland
Gebundene Ausgabe. Zustand: Neu. In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. Sprache: Englisch Gewicht in Gramm: 608. Artikel-Nr. IB-22172109
Anzahl: 2 verfügbar